Positron emission tomographic (PET) radiopharmaceuticals
There are two main sources of PET radiopharmaceuticals: cyclotron produced and generator produced.
KeywordsGlucose Utilization Hexokinase Activity Intracoronary Streptokinase Rubidium Chloride Oxygen Carbon Dioxide
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 3.Reivich, M., Kuhl, D., Wolf, A. et al. (1979) The [F-18] fluorodeoxy glucose method for the measurement of local cerebral glucose utilization in man. Circ. Res., 44, 127–37.Google Scholar
- 5.Product Information (1986) Positron Emission Tomography Planning Guide, Computer Technology and Imaging, TN.Google Scholar
- 7.Gould, K.L., Goldstein, R.A., Mullani, N.A. et al. (1986) Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using rubidium-82. J. Am. Coll. Cardiol., 7, 775–89.CrossRefGoogle Scholar
- 8.Goldstein, R.A., Mullani, N.A., Wong. W.-H. et al. (1986) Positron imaging of myocardial infarction with rubidium-82. J. Nucl. Med., 27, 1824–29.Google Scholar
- 9.Goldstein, R.A., Mullani, N.A., Fisher, D.J. et al. (1983) Myocardial perfusion with rubidium-82. II. Effects of metabolic and pharmaceutical interventions. J. Nucl. Med., 24, 907–15.Google Scholar
- 12.Sheehan, R.M. and Renkin, E.M. (1972) Capillary interstitial and cell membrane barriers to blood-tissue transport of potassium and rubidium in mammalian skeletal muscle. Circ. Res., 30, 588–607.Google Scholar
- 15.Gallagher, B.M., Fowler, J.S., Gutterson, N.I. et al. (1978) Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J. Nucl. Med., 19, 1154–61.Google Scholar
- 16.Lambrecht, R.M. and Wolf, A.P. (1973) Cyclotron and short-lived halogen isotopes for radiopharmaceutical applications, in Radiopharmaceuticals and Labeled Compounds, IAEA-SM-171/79, Copenhagen, Denmark.Google Scholar
- 18.Phelps, M.E., Hoffman, E.J., Selin, C. et al. (1978) Investigation of [18F] 2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J. Nucl. Med., 19, 1311–19.Google Scholar
- 21.Gallaghar, B.M., Ansari, A., Atkins, H. et al. (1977) Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in-vivo: tissue distribution and imaging studies in animals. J. Nucl Med., 18, 990–96.Google Scholar
- 22.Mejia, A.A., Nakamura, T., Masatoshi, I. et al. (1991) Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J. Nucl. Med., 32, 699–706.Google Scholar
- 23.West, J.B. and Dollery, C.T. (1962) Uptake of oxygen-15-labeled CO2 compared with carbon-11-labeled CO2 in lung. J. Appl. Physiol, 17, 14–20.Google Scholar
- 24.Bigler, R.E. and Sgouros, G. (1983) Biological analysis and dosimetry for 15O-labeled O2∲ CO2 and CO gases administered continuously by inhalation. J. Nucl. Med., 24, 431–37.Google Scholar
- 25.Harper, P.V., Lathrop, K.A., Krizek, H. et al. (1972) Clinical feasibility of myocardial imaging with 13NH3. J. Nucl Med., 13, 278–80.Google Scholar
- 26.Harper, P.V., Lathrop, K.A., Krizek, H. (1975) 13N radiopharmaceuticals, in Radiopharmaceuticals (eds G. Subramanian, B.A. Rhodes, J.F. Cooper and V.J. Sodd), The Society of Nuclear Medicine, New York, pp. 180–83.Google Scholar
- 27.Monahan, W.G., Tilbury, R.S. and Laughlin, J.S. (1972) Uptake of 13N-labeled ammonia. J. Nucl Med., 13, 274–77.Google Scholar
© Azuwuike Owunwanne, Mohan Patel and Samy Sadek 1995